Lite Paper: Real-World PD-L1 Testing Data Provides Insight into the Evolving Immuno-oncology Landscape
Case Study: How Pharma Uses NeoGenomics Real-World Oncology Data to Accelerate Biomarker Adoption and Commercial Launch
Taking Spatial Toward the Clinic: DeciBio’s Q&A with Sandy Au of NeoGenomics
Blog originally posted on Decibio Insights here.
Is IHC going to exhaust our archival blocks the way single gene testing used to?
Over the past year we have seen unprecedented demand for IHC assay development services with the goal of creating a prototype CDx assay.
Scott Reid
NeoGenomics announces speaker program, ‘Minimal Residual Disease in Colorectal Cancer’
NeoGenomics is pleased to announce a speaker program titled ‘Minimal Residual Disease in Colorectal Cancer.’
IVDR at NeoGenomics
With the recent application of IVDR on May 26, 2022, there are new regulatory standards that oversee the sales and use of IVDs for the EU.
James Yen